Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean glycol and silicon dioxide and sodium monofluorophosphate?
Displaying drugs 651 - 675 of 14431 in total

Human Rho(D) immune globulin

Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the...
Approved
Investigational
Matched Description: … Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Thyroglobulin

Thyroglobulin (also known as Tg) is an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3). The active form of thyroxine, triiodothyronine, is produced both within the thyroid gland and periphery by 5'-deiodinase. Patients with Hashimoto's thyroiditis or Graves' disease, frequently...
Approved
Withdrawn
Matched Description: … an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and ... The active form of thyroxine, triiodothyronine, is produced both within the thyroid gland and periphery …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Pancrelipase amylase

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. The pancrelipase amylase is a...
Approved
Matched Description: … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and ... mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and ... [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide …
Matched Categories: … Enzymes and Coenzymes …

Corynebacterium diphtheriae CRM197 protein

Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …

Trospium

Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and...
Approved
Matched Description: … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes ... [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007 …
Matched Categories: … trospium and analgesics ... Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …

Obinutuzumab

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Gliclazide

Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release...
Approved
Matched Description: … increase the number and sensitivity of insulin receptors. ... Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. ... The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Filgrastim

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human...
Approved
Matched Description: … [L40719] It has a number of therapeutic uses, including the management and prevention of infections and ... acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and ... [L40714] Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Acarbose

Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and...
Approved
Investigational
Matched Description: … starches and oligo-, tri-, and disaccharides into absorbable simple sugars. ... the subsequent postprandial increase in blood glucose and insulin levels. ... It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal …
Matched Categories: … metformin and acarbose ... Alimentary Tract and Metabolism …

Inebilizumab

Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients ... [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Piperazine

Piperazine is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. Upon entry into the systemic circulation, the drug is partly oxidized and partly...
Approved
Vet approved
Matched Description: … Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate ... Upon entry into the systemic circulation, the drug is partly oxidized and partly eliminated as an unchanged …
Matched Categories: … Piperazine and Derivatives ... Antiparasitic Products, Insecticides and Repellents …

Thiamylal

A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
Approved
Vet approved
Matched Salts name: … Thiamylal sodium …
Matched Categories: … Hypnotics and Sedatives …

Teprotumumab

Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA...
Approved
Investigational
Matched Description: … tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive ... disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and ... Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ravulizumab

Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... atypical hemolytic uremic syndrome in children and adults. ... was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Stem bromelain

The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA Label]. Bromelain itself belongs to a category of protein-digesting enzymes that are...
Approved
Investigational
Matched Description: … Although both fruit and stem bromelain are prepared differently and contain different enzymatic compositions ... The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn ... wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand …
Matched Categories: … Enzymes and Coenzymes …

Ferric pyrophosphate citrate

Ferric pyrophosphate citrate is a soluble iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate and citrate. FPC is categorized in...
Approved
Investigational
Matched Description: … The ferric ion is strongly complexed by pyrophosphate and citrate. ... Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation …
Matched Categories: … Enzymes and Coenzymes …

Secukinumab

Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Zinc ascorbate

Approved
Nutraceutical
Matched Categories: … Vitamin C and analogues ... Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …

Pegfilgrastim

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … pharmacokinetic profile and conditions of use. ... than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and ... Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Interferon alfa-2a

Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is...
Approved
Investigational
Matched Description: … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Ramucirumab

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … , and migration of human endothelial cells. ... By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby ... VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Pembrolizumab

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes...
Approved
Matched Description: … as interchain bonds and 23 interchain bonds. ... [A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages ... [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Nifurtimox

Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis. The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without...
Approved
Investigational
Matched Description: … a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and ... L15366] The CDC estimates that approximately 8 million people in Central America, South America, and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Emapalumab

Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough...
Approved
Investigational
Matched Description: … , L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and ... Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Doconexent

A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and...
Approved
Investigational
Matched Description: … , and retina thus plays an important role in their development and function. ... A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement ... It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin …
Matched Salts name: … Doconexent sodium …
Displaying drugs 651 - 675 of 14431 in total